Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
Antengene Logs Slimmer Loss in 2023 Despite Revenue Drop
Antengene's (HKG:6996) attributable loss narrowed to 581.2 million yuan, or 0.94 yuan per share, in 2023 from 601.5 million yuan, or 0.97 yuan per share, in 2022, according to the company's annual rep
德琪醫藥-B:2023 年度報告
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Hong Kong pharmaceutical stocks bucked the trend, and Pharmacovigilance led their sector. Is the “Biosafety Act” or a biological variable?
① Why is the market paying attention to the Biosafety Act? ② How has Yao Ming Kangde performed recently?
ANTENGENE-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION AND CHANGE IN USE...
Yao Ming Kangde was removed from BIO membership! Where will the domestic innovative drug sector go?
The path to the rise of innovative drugs doesn't seem easy!
Not only is Daimo bullish, but Xiaoma has taken steps to increase its holdings of the drug Ming Kangde. Major international banks are turning one after another, and the Hong Kong stock pharmaceutical industry is welcoming a “crouching and leap”?
① Hong Kong stocks of Innovative Pharmaceuticals soared at the end of yesterday. Collumbotai Biotech B rose 14.9%; Rongchang Biotech rose 14.8%; Connoya B rose 12.8%; ② Although “Yao Mao” Pharmaceutical Kangde Hong Kong shares closed down 1.16%, the decline narrowed sharply at the end of the session, and J.P. Morgan increased its holdings by 1.654 million shares, or HK$77.68 million.
Express News | China Artificial Intelligence Industry Development Alliance plans to initiate the establishment of a “Biomedical Industry Working Group”
Deqi Pharmaceutical-B (06996.HK) held a board meeting on March 22 to consider and approve the annual results
Gelonghui March 11 | Deqi Pharmaceutical-B (06996.HK) announced that the company will hold a board meeting on March 22, 2024 (Friday) to consider and approve (among others) the results of the company and its subsidiaries for the year ended December 31, 2023 and their announcements.
ANTENGENE-B: NOTICE OF DATE OF BOARD MEETING
What is the biggest highlight of medicine this year? The new version of the basic drug catalogue expands traditional Chinese medicine and pediatric medicine and is expected to usher in benefits|Traditional Chinese Medicine 2024 outlook
Finance Association, Feb. 29 (Reporter Zhang Liangde) “The biggest highlight of the pharmaceutical industry this year is the expansion of the new version of the basic drug catalogue.
Hong Kong Stock Concept Tracking | Pharmaceutical companies' pricing is being loosened? The innovative drug sector is expected to usher in a beta market (with concept stocks)
On February 5, the National Health Insurance Administration issued a letter to relevant industry associations seeking comments on the “Notice on Establishing a Initial Price Formation Mechanism for Newly Launched Chemicals to Encourage High-Quality Innovation (Draft for Comments)”.
Heavy policy! “One province connected to the Internet, nationwide access” innovative drug market entry welcomed benefits
On the eve of the Lunar New Year, the pharmaceutical industry once again ushered in a major favorable policy.
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
No Data